<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03633266</url>
  </required_header>
  <id_info>
    <org_study_id>10007</org_study_id>
    <nct_id>NCT03633266</nct_id>
  </id_info>
  <brief_title>Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy</brief_title>
  <official_title>Feasibility Study of Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wenzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of vitreoretinal surgery combined with anti-VEGF therapy
      in the replacement of intraoperative PRP in PDR therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in best-corrected visual acuity (BCVA)</measure>
    <time_frame>3 years</time_frame>
    <description>Assessed using the ETDRS protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in visual field</measure>
    <time_frame>3 years</time_frame>
    <description>Assessed on Humphery(30-2 and 60-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chang from baseline in sructure of retina</measure>
    <time_frame>3 years</time_frame>
    <description>Assessed on Optical Coherence Tomography(OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chang from baseline in retinal neovascularization</measure>
    <time_frame>3 years</time_frame>
    <description>Assessed on Fundus Fluorescein Angiography(FFA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Anti-VEGF</condition>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <condition>PRP</condition>
  <condition>Vitrectomy</condition>
  <arm_group>
    <arm_group_label>anti-VEGF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental group: vitreoretinal surgery combined with intraoperative anti-VEGF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group: vitreoretinal surgery combined with intraoperative PRP</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anti-VEGF</intervention_name>
    <description>vitreoretinal surgery combined with intraoperative anti-VEGF</description>
    <arm_group_label>anti-VEGF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PRP</intervention_name>
    <description>vitreoretinal surgery combined with intraoperative PRP</description>
    <arm_group_label>PRP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ageâ‰¥18 years old;

          2. type 1 or type 2 diabetes.

          3. proliferative diabetic retinopathy with vitreous hemorrhage, and conservative
             treatment of vitreous hemorrhage without obvious absorption for 1 month requires
             vitreoretinal surgery;

          4. The postoperative refractive medium is clear and the pupil is large enough to obtain
             sufficient clear fundus

        Exclusion Criteria:

          1. Previously received panretinal photocoagulation or unfinished panretinal
             photocoagulation;

          2. Pulling retinal detachment involving the macula or the presence of extensive fiber
             proliferation requires silicone oil filling;

          3. anterior chamber neovascularization or neovascular glaucoma;

          4. other vascular diseases such as retinal vein occlusion, arterial occlusion, etc;

          5. received intraocular anti-VEGF therapy or triamcinolone acetonide treatment which are
             still in the treatment period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Wei, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Eye Hospital of Wenzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong Wei, M.D</last_name>
    <phone>+86 15057551266</phone>
    <email>weiyongdoctor@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei lin, M.D</last_name>
    <phone>+86 13587560390</phone>
    <email>linweiysg@163.com</email>
  </overall_contact_backup>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>Xiangtian Zhou</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

